• Date: July 24, 2018

Spanish biotechnology companies received €149 million last year, 17% more than in 2016. The sectors economic impact was worth 0.7% of Spanish GDP (€7.3 billion), and helped create over 108,000 jobs. These are some of the conclusions reached in the latest Annual Report published by the Spanish Association of Biotech Companies (ASEBIO).

In a breakdown by type of financial operation, the report highlights €93.7 million spent on increased private equity investments, €41 million in share capital increases, and €10.8 million on related operations and participation loans. There were also significant levels of venture capital activity in 2017, with entities in the sector, such as Caixa Capital Risc, investing a total of €30 million.

The report also provides data from the 2016 Innovation in Companies Survey carried out by the Spanish National Statistics Institute, showing that €617 million were invested in R&D in the Spanish biotechnology sector, 6.6% more than in 2015. The main area of activity is human health (66.8%), followed by food (23.5%). Most companies in the sector are found in the autonomous community of Catalonia (19.3%), followed by Andalusia (13.5%) and Galicia (8.6%).

More news

July 12, 2018

Applications open for The Scientist's Top 10 Innovations 2018

The magazine The Scientist has spent a decade publishing the latest biomedicine innovations in its annual Top 10 Innovations contest. Applications are already open for this year’s competition.

July 05, 2018

Biocat launches a programme to find investors for early stage projects

The Investment Readiness Series is a new programme run by Biocat, offering mentoring and the chance to meet potential investors who are looking for healthcare research projects in the early stages of the innovation process.

June 26, 2018

COMPASS offers a mentoring programme on responsible innovation for SMEs

Start-ups and SMEs are invited to apply to the consultancy and mentoring scheme offered by the EU-funded project Responsible Innovation COMPASS.